Aktis Oncology: Differentiated Miniprotein Radiopharma Platform Underpins Buy Rating and Multi-Billion Dollar Sales Potential

Aktis Oncology, Inc. (AKTS) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren.

Tyler Van Buren has given his Buy rating due to a combination of factors tied to Aktis Oncology’s differentiated radiopharma platform and sizable commercial opportunity. He believes the company’s proprietary miniprotein technology can move targeted radiotherapy beyond the limitations of first-generation agents, which were either constrained by small-molecule chemistry or challenged by antibody-related toxicity. Aktis’ miniproteins are designed to combine antibody-like binding strength with efficient tumor penetration and fast bloodstream clearance, while also enabling access to targets that have historically been hard to drug. When linked to a powerful Ac-225 alpha payload, this approach is projected to open up a much larger pool of solid tumor indications than existing radioligand therapies can address.

Tyler Van Buren also points to encouraging early data from lead candidates AKY-1189 (targeting Nectin-4) and AKY-2519 (targeting B7-H3), which have shown strong, durable tumor localization with limited exposure to healthy tissues, reducing perceived clinical risk ahead of Phase Ib and dosimetry readouts. For AKY-1189, he highlights especially compelling potential in second-line metastatic urothelial carcinoma and triple-negative breast cancer, where the withdrawal or migration of antibody-drug conjugates has left a clear therapeutic gap. His financial model calls for more than $5 billion in combined sales by 2035, including a $2.4 billion contribution from AKY-1189 in just a subset of its addressable population, which he views as conservative. Coupled with what he characterizes as a top-tier management team capable of executing on clinical and commercial milestones, these elements collectively support his Buy recommendation on Aktis Oncology, Inc.

In another report released today, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $30.00 price target.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AKTS in relation to earlier this year.